Microbot Medical Announces Closing of $2.35 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Core Viewpoint - Microbot Medical Inc. has successfully closed a registered direct offering and a concurrent private placement, raising approximately $2.35 million to support the development of its LIBERTY® Robotic System and other corporate purposes [1][3]. Group 1: Offering Details - The company sold 1,566,669 shares of common stock at a price of $1.50 per share [1]. - In addition, the company issued series F preferred investment options to purchase up to 3,133,338 shares of common stock, also at an exercise price of $1.50 per share, which are immediately exercisable for two years [1]. - H.C. Wainwright & Co. acted as the exclusive placement agent for these offerings [2]. Group 2: Use of Proceeds - The net proceeds from the offerings will be utilized for the continued development, commercialization, and regulatory activities of the LIBERTY® Robotic System [3]. - Additional applications derived from the company's existing intellectual property portfolio will also be developed, along with general working capital and corporate purposes [3]. Group 3: Company Overview - Microbot Medical Inc. is a pre-clinical medical device company focused on transformational micro-robotic technologies aimed at improving clinical outcomes and accessibility within the human body [7]. - The LIBERTY® Endovascular Robotic Surgical System is designed to enhance surgical robotics in endovascular procedures by reducing the need for large equipment and minimizing radiation exposure [8].